Editas Medicine Inc. (NASDAQ: EDIT) appointed Dan Ory, M.D., as chief medical officer on Sept. 8, effective immediately.
Based in Cambridge, Mass., the company said Ory will oversee its clinical development strategy and operations as it advances EDIT-401, its lead in vivo development candidate for treating hyperlipidemia, toward clinical trials.
Ory brings more than 25 years of experience in biotechnology leadership, cardiovascular medicine and genetic medicine development. He most recently served as chief medical officer at Arbor Biotechnologies, where he oversaw a global clinical trial for its lead in vivo gene editing program. Prior to that, he was CMO at Casma Therapeutics, leading clinical development programs for rare genetic and neurodegenerative diseases.
He spent over two decades at Washington University School of Medicine in St. Louis, where he held the Alan A. and Edith L. Wolff Professorship of Cardiology. His research there focused on cholesterol metabolism and Niemann-Pick disease type C.
Ory holds an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed postdoctoral training at the Whitehead Institute at MIT, an internal medicine residency at Brigham and Women’s Hospital and a cardiology fellowship at Massachusetts General Hospital. He has authored more than 160 peer-reviewed publications and is a fellow of the American Association for the Advancement of Science.
Editas Medicine is a gene editing company developing CRISPR-based in vivo medicines. It holds exclusive licenses to the Broad Institute’s Cas12a patent estate and the Broad Institute and Harvard University’s Cas9 patent estates for human medicines.
